12,470 results match your criteria Parkinson Disease Dementia


Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis.

Parkinsonism Relat Disord 2022 Jun 20. Epub 2022 Jun 20.

Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; KITE UHN Toronto Rehabilitation Institute, Toronto, Ontario, Canada. Electronic address:

Background: Mixed evidence supports blood-brain barrier (BBB) dysfunction in Lewy body spectrum diseases.

Methods: We compare biofluid markers in people with idiopathic Parkinson's disease (PD) and people with PD dementia (PDD) and/or dementia with Lewy bodies (DLB), compared with healthy controls (HC). Seven databases were searched up to May 10, 2021. Read More

View Article and Full-Text PDF

Dural Arteriovenous Fistula as a Reversible Cause of Progressive Parkinsonism and Dementia: A Case Report.

Neurohospitalist 2022 Jul 27;12(3):559-562. Epub 2022 Apr 27.

Neuroradiology Unit, San Camillo-Forlanini Hospital, Rome, Italy.

A dural arteriovenous fistula (DAVF) is an abnormal direct connection between an intracranial artery and the dural venous sinus. In rare cases, DAVF might show rapidly progressive dementia onset with extrapyramidal signs, often misdiagnosed as Parkinson disease or vascular parkinsonism and, therefore, pharmacological treatments are ineffective. Here, we report the case of 84-year-old man with rapidly progressive parkinsonism and dementia who was initially treated with levodopa without any improvement. Read More

View Article and Full-Text PDF

Deep learning based low-activity PET reconstruction of [C]PiB and [F]FE-PE2I in neurodegenerative disorders.

Neuroimage 2022 Jun 23:119412. Epub 2022 Jun 23.

Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Denmark. Electronic address:

Purpose: Positron Emission Tomography (PET) can support a diagnosis of neurodegenerative disorder by identifying disease-specific pathologies. Our aim was to investigate the feasibility of using activity reduction in clinical [F]FE-PE2I and [C]PiB PET/CT scans, simulating low injected activity or scanning time reduction, in combination with AI-assisted denoising.

Methods: A total of 162 patients with clinically uncertain Alzheimer's disease underwent amyloid [C]PiB PET/CT and 509 patients referred for clinically uncertain Parkinson's disease underwent dopamine transporter (DAT) [F]FE-PE2I PET/CT. Read More

View Article and Full-Text PDF

Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease.

Parkinsonism Relat Disord 2022 Jun 8. Epub 2022 Jun 8.

Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Department of Medicine, Barcelona, Spain; Sant Pau Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Centro de Investigación en Red - Enfermedades Neurodegenerativas (CIBERNED), Spain.

Background: Cognitive dysfunction is a disabling complication in Parkinson's disease (PD). Accuracy of diagnosis of mild cognitive impairment in PD (PD-MCI) depends on the tests performed, which limits results generalization. Blood-based biomarkers could provide additional objective information for PD-MCI diagnosis and progression. Read More

View Article and Full-Text PDF

[Atypical Parkinson's syndrome in old age].

Z Gerontol Geriatr 2022 Jun 24. Epub 2022 Jun 24.

Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Breslauerstr. 201, 90471, Nürnberg, Deutschland.

Atypical Parkinson syndromes represent a neuropathologically heterogeneous group and include the clinical entities dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). The DLB and MSA are characterized by deposition of the protein alpha-synuclein (synucleinopathy), PSP and CBD are characterized by deposition of tau protein, often in the form of neurofibrillary tangles in nerve and glial cells (tauopathy). Misfolding and aggregation of the aforementioned proteins causes degeneration of the affected cell populations but the disease also spreads to anatomically neighboring brain regions, thus contributing to disease progression. Read More

View Article and Full-Text PDF

Genome Sequencing in the Parkinson Disease Clinic.

Neurol Genet 2022 Aug 9;8(4):e200002. Epub 2022 Jun 9.

Department of Neurology (E.J.H., S.R., H.S., J.J., J.M. Shulman), and Parkinson's Disease Center and Movement Disorders Clinic (E.J.H., C.S., J.J., J.M. Shulman), Baylor College of Medicine, Houston, TX. E.J. Hill is now with Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH; Department of Molecular and Human Genetics (L.A.R., J.C.F., P.J.V., R.A.G., J.M. Shulman), Department of Pediatrics (R.A.-O., Z.L.), and Department of Neuroscience (J.D., J.M. Shulman), Baylor College of Medicine, Houston, TX; Department of Neurology (E.S., J.M. Savitt, R.v.C., N.D., L.M.S.), University of Maryland School of Medicine, Baltimore; Center for Alzheimer's and Neurodegenerative Diseases (H.S., A.L.M., Z.L., J.M. Shulman), Human Genome Sequencing Center (H.D., S.S., S.D.-P., D.M.M., R.A.G.), and Center for Medical Ethics and Health Policy (A.L.M.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (Z.L., J.M. Shulman), Texas Children's Hospital, Houston.

Background And Objectives: Genetic variants affect both Parkinson disease (PD) risk and manifestations. Although genetic information is of potential interest to patients and clinicians, genetic testing is rarely performed during routine PD clinical care. The goal of this study was to examine interest in comprehensive genetic testing among patients with PD and document reactions to possible findings from genome sequencing in 2 academic movement disorder clinics. Read More

View Article and Full-Text PDF

Recent Advances on the Role of Brain-Derived Neurotrophic Factor (BDNF) in Neurodegenerative Diseases.

Int J Mol Sci 2022 Jun 19;23(12). Epub 2022 Jun 19.

Department of Physiology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.

Neurotrophins, such as brain-derived neurotrophic factor (BDNF), are essential for neuronal survival and growth. The signaling cascades initiated by BDNF and its receptor are the key regulators of synaptic plasticity, which plays important role in learning and memory formation. Changes in BDNF levels and signaling pathways have been identified in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, and have been linked with the symptoms and course of these diseases. Read More

View Article and Full-Text PDF

Differentially Expressed miRNAs in Age-Related Neurodegenerative Diseases: A Meta-Analysis.

Genes (Basel) 2022 Jun 9;13(6). Epub 2022 Jun 9.

Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, 1105 AZ Amsterdam, The Netherlands.

To date, no neurodegenerative diseases (NDDs) have cures, and the underlying mechanism of their pathogenesis is undetermined. As miRNAs extensively regulate all biological processes and are crucial regulators of healthy brain function, miRNAs differentially expressed in NDDs may provide insight into the factors that contribute to the emergence of protein inclusions and the propagation of deleterious cellular environments. A meta-analysis of miRNAs dysregulated in Alzheimer's disease, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies and frontotemporal lobar degeneration (TDP43 variant) was performed to determine if diseases within a proteinopathy have distinct or shared mechanisms of action leading to neuronal death, and if proteinopathies can be classified on the basis of their miRNA profiles. Read More

View Article and Full-Text PDF

Examples of Inverse Comorbidity between Cancer and Neurodegenerative Diseases: A Possible Role for Noncoding RNA.

Cells 2022 06 15;11(12). Epub 2022 Jun 15.

Oasi Research Institute, IRCCS (Istituti di Ricovero e Cura a Carattere Scientifico), Italian Ministry of Health, 94018 Troina, Italy.

Cancer is one of the most common causes of death; in parallel, the incidence and prevalence of central nervous system diseases are equally high. Among neurodegenerative diseases, Alzheimer's dementia is the most common, while Parkinson's disease (PD) is the second most frequent neurodegenerative disease. There is a significant amount of evidence on the complex biological connection between cancer and neurodegeneration. Read More

View Article and Full-Text PDF

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.

Acta Neuropathol Commun 2022 Jun 22;10(1):90. Epub 2022 Jun 22.

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.

Currently, there is a need for diagnostic markers in Lewy body disorders (LBD). α-synuclein (αSyn) RT-QuIC has emerged as a promising assay to detect misfolded αSyn in clinically or neuropathologically established patients with various synucleinopathies. In this study, αSyn RT-QuIC was used to analyze lumbar CSF in a clinical cohort from the Swedish BioFINDER study and postmortem ventricular CSF in a neuropathological cohort from the Arizona Study of Aging and Neurodegenerative Disorders/Brain and Body Donation Program (AZSAND/BBDP). Read More

View Article and Full-Text PDF

Genetics of validated Parkinson's disease subtypes in the Oxford Discovery and Tracking Parkinson's cohorts.

J Neurol Neurosurg Psychiatry 2022 Jun 22. Epub 2022 Jun 22.

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Objectives: To explore the genetics of four Parkinson's disease (PD) subtypes that have been previously described in two large cohorts of patients with recently diagnosed PD. These subtypes came from a data-driven cluster analysis of phenotypic variables.

Methods: We looked at the frequency of genetic mutations in glucocerebrosidase (GBA) and leucine-rich repeat kinase 2 against our subtypes. Read More

View Article and Full-Text PDF

Pinpointing novel risk loci for Lewy body dementia and the shared genetic etiology with Alzheimer's disease and Parkinson's disease: a large-scale multi-trait association analysis.

BMC Med 2022 Jun 22;20(1):214. Epub 2022 Jun 22.

Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.

Background: The current genome-wide association study (GWAS) of Lewy body dementia (LBD) suffers from low power due to a limited sample size. In addition, the genetic determinants underlying LBD and the shared genetic etiology with Alzheimer's disease (AD) and Parkinson's disease (PD) remain poorly understood.

Methods: Using the largest GWAS summary statistics of LBD to date (2591 cases and 4027 controls), late-onset AD (86,531 cases and 676,386 controls), and PD (33,674 cases and 449,056 controls), we comprehensively investigated the genetic basis of LBD and shared genetic etiology among LBD, AD, and PD. Read More

View Article and Full-Text PDF

[A new paradigm for the development of neurodegenerative diseases on the example of Alzheimer's disease and Parkinson's disease.]

Adv Gerontol 2022 ;35(2):263-273

S.M.Kirov Military-Medical Academy, 6 Academician Lebedev str., St. Petersburg 194044, Russian Federation, e-mail:

The role of neuronal inflammation developing during the formation of amyloid plaques and Lewy bodies has been investigated. The influence of various exogenous and endogenous factors on the development of neuroinflammation has been established, but the role of various infectious agents in the development of this process has been much less studied. Today, the existence of a universal trigger mechanism of the neurodegenerative process is obvious: a specific pathogen of a bacterial or viral nature (including a long-term persistent in the nervous tissue in a latent state), reactivating, penetrates into certain cerebral structures, where it is influenced by either Aβ or resident macrophages of the central nervous system, which, in turn, are activated and induce the release of pro-inflammatory cytokines, leading to the development of neuronal inflammation, autophagy and neurodegeneration. Read More

View Article and Full-Text PDF

Morphological basis of Parkinson disease-associated cognitive impairment: an update.

Authors:
Kurt A Jellinger

J Neural Transm (Vienna) 2022 Jun 20. Epub 2022 Jun 20.

Institute of Clinical Neurobiology, Alberichgasse 5/13, 1150, Vienna, Austria.

Cognitive impairment is one of the most salient non-motor symptoms of Parkinson disease (PD) that poses a significant burden on the patients and carers as well as being a risk factor for early mortality. People with PD show a wide spectrum of cognitive dysfunctions ranging from subjective cognitive decline and mild cognitive impairment (MCI) to frank dementia. The mean frequency of PD with MCI (PD-MCI) is 25. Read More

View Article and Full-Text PDF

Central nervous system effects of 5-HT receptors: a potential target for neurodegenerative diseases.

Mol Med 2022 Jun 20;28(1):70. Epub 2022 Jun 20.

Department of Neurology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

5-HT receptors (5-HTR) are the most recently identified among the family of serotonin receptors. Their role in health and disease, particularly as mediators of, and druggable targets for, neurodegenerative diseases, is incompletely understood. Unlike other serotonin receptors, for which abundant preclinical and clinical data evaluating their effect on neurodegenerative conditions exist, the available information on the role of the 5-HTR receptor is limited. Read More

View Article and Full-Text PDF

Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease.

Mov Disord 2022 Jun 20. Epub 2022 Jun 20.

Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London.

Background: Cognitive impairment is common in neurological presentations of Wilson's disease (WD). Various domains can be affected, and subclinical deficits have been reported in patients with hepatic presentations. Associations with imaging abnormalities have not been systematically tested. Read More

View Article and Full-Text PDF

Green Tea Intake and Parkinson's Disease Progression: A Mendelian Randomization Study.

Front Nutr 2022 26;9:848223. Epub 2022 May 26.

Laboratory of Neurodegenerative Disorders, Department of Neurology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.

Epidemiological studies have suggested green tea intake was associated with a reduced risk of Parkinson's disease (PD). However, whether green tea intake has an effect on PD progression is unknown. To evaluate the role of green tea intake in PD progression, we conducted a two-sample Mendelian randomization analysis using summary statistics from genome-wide association studies of green tea intake ( = 64,949), age at onset ( = 28,568) and progression ( = 4,093) of PD. Read More

View Article and Full-Text PDF

Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings.

PET Clin 2022 Jul;17(3):479-494

Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.

Positron emission tomography (PET) has been a key component in the diagnostic armamentarium for assessing neurodegenerative diseases such as Alzheimer or Parkinson disease. PET imaging has been useful for diagnosing these disorders, identifying their pathophysiology, and following their treatment. Further, PET imaging has been extensively used for both clinical and research purposes, particularly for helping with potential therapeutic approaches for managing neurodegenerative diseases. Read More

View Article and Full-Text PDF

A biological classification of Huntington's disease: the Integrated Staging System.

Lancet Neurol 2022 Jul;21(7):632-644

CHDI Management/CHDI Foundation, Princeton, NJ, USA; Clinical Pharmacology Laboratory, Faculdade de Medicina de Lisboa, University of Lisbon, Lisbon, Portugal. Electronic address:

The current research paradigm for Huntington's disease is based on participants with overt clinical phenotypes and does not address its pathophysiology nor the biomarker changes that can precede by decades the functional decline. We have generated a new research framework to standardise clinical research and enable interventional studies earlier in the disease course. The Huntington's Disease Integrated Staging System (HD-ISS) comprises a biological research definition and evidence-based staging centred on biological, clinical, and functional assessments. Read More

View Article and Full-Text PDF

The Weekly Calendar Planning Activity to Assess Functional Cognition in Parkinson Disease.

OTJR (Thorofare N J) 2022 Jun 17:15394492221104075. Epub 2022 Jun 17.

Mercy College, Dobbs Ferry, NY, USA.

The Weekly Calendar Planning Activity (WCPA) may improve understanding of functional cognition in people with Parkinson disease (PwPD) without dementia. We aimed to determine if WCPA performance (a) discriminates between PwPD with and without cognitive impairment and healthy controls and (b) correlates with other indicators of cognition and daily function. This was a cross-sectional study. Read More

View Article and Full-Text PDF

Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target.

Authors:
Jinbin Xu

Curr Top Behav Neurosci 2022 Jun 17. Epub 2022 Jun 17.

Division of Radiological Sciences, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.

Parkinson disease (PD) dementia, pathologically featured as nigrostriatal dopamine (DA) neuronal loss with motor and non-motor manifestations, leads to substantial disability and economic burden. DA therapy targets the DA D3 receptor (D3R) with high affinity and selectivity. The pathological involvement of D3R is evidenced as an effective biomarker for disease progression and DA agnostic interventions, with compensations of increased DA, decreased aggregates of α-synuclein (α-Syn), enhanced secretion of brain-derived neurotrophic factors (BDNF), attenuation of neuroinflammation and oxidative damage, and promoting neurogenesis in the brain. Read More

View Article and Full-Text PDF

Glutamatergic transmission and receptor expression in the synucleinopathy h-α-synL62 mouse model: Effects of hydromethylthionine.

Cell Signal 2022 Jun 13;97:110386. Epub 2022 Jun 13.

School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. Electronic address:

The accumulation of alpha-synuclein (α-Syn) into Lewy bodies in cortical and subcortical regions has been linked to the pathogenesis of synucleinopathies such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB). While there is a strong link between synuclein aggregates and the reduction in dopamine function in the emergence of PD, less is known about the consequences of α-Syn accumulation in glutamatergic neurons and how this could be exploited as a therapeutic target. Transgenic h-α-synL62 (L62) mice, in which synuclein aggregation is achieved through the expression of full-length human α-Syn fused with a signal sequence peptide, were used to characterise glutamatergic transmission using a combination of behavioural, immunoblotting, and histopathological approaches. Read More

View Article and Full-Text PDF

Predictors of rapid eye movement sleep behavior disorder in patients with Parkinson's disease based on random forest and decision tree.

PLoS One 2022 16;17(6):e0269392. Epub 2022 Jun 16.

Department of Medical, Huzhou Normal University, Huzhou, Zhejiang Province, China.

Background And Objectives: Sleep disorders related to Parkinson's disease (PD) have recently attracted increasing attention, but there are few clinical reports on the correlation of Parkinson's disease patients with rapid eye movement (REM) sleep behavior disorder (RBD). Therefore, this study conducted a cognitive function examination for Parkinson's disease patients and discussed the application effect of three algorithms in the screening of influencing factors and risk prediction effects.

Methods: Three algorithms (logistic regression, machine learning-based regression trees and random forest) were used to establish a prediction model for PD-RBD patients, and the application effects of the three algorithms in the screening of influencing factors and the risk prediction of PD-RBD were discussed. Read More

View Article and Full-Text PDF

Visual hallucinations in elderly veterans: Highlighting the issue of premature diagnosis of Lewy Body Dementia.

Int J Geriatr Psychiatry 2022 Jul;37(7)

Department of Psychiatry, Washington DC VA Medical Center, Washington, District of Columbia, USA.

View Article and Full-Text PDF

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases.

Heliyon 2022 Jun 4;8(6):e09575. Epub 2022 Jun 4.

Department of Biotechnology, Kalasalingam Academy of Research and Education, Krishnankoil, 626126, Tamilnadu, India.

The function of the brain can be affected by various factors that include infection, tumor, and stroke. The major disorders reported with altered brain function are Alzheimer's disease (AD), Parkinson's disease (PD), dementia, brain cancer, seizures, mental disorders, and other movement disorders. The major barrier in treating CNS disease is the blood-brain barrier (BBB), which protects the brain from toxic molecules, and the cerebrospinal fluid (CSF) barrier, which separates blood from CSF. Read More

View Article and Full-Text PDF

Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Drugs Aging 2022 Jun 16;39(6):417-439. Epub 2022 Jun 16.

Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson, NS-PARK/FCRIN Network, 59 Boulevard Pinel, 69500, Bron, France.

Depression is one of the most frequent and burdensome non-motor symptoms in Parkinson's disease (PD), across all stages. Even when its severity is mild, PD depression has a great impact on quality of life for these patients and their caregivers. Accordingly, accurate diagnosis, supported by validated scales, identification of risk factors, and recognition of motor and non-motor symptoms comorbid to depression are critical to understanding the neurobiology of depression, which in turn determines the effectiveness of dopaminergic drugs, antidepressants and non-pharmacological interventions. Read More

View Article and Full-Text PDF

The Impact of Type 2 Diabetes in Parkinson's Disease.

Mov Disord 2022 Jun 14. Epub 2022 Jun 14.

Neurodegeneration Biology Laboratory, Francis Crick Institute, London, United Kingdom.

Background: Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson's disease (PD), but its effect on disease progression is not well understood.

Objective: The aim of this study was to investigate the influence of T2DM on aspects of disease progression in PD.

Methods: We analyzed data from the Tracking Parkinson's study to examine the effects of comorbid T2DM on PD progression and quality of life by comparing symptom severity scores assessing a range of motor and nonmotor symptoms. Read More

View Article and Full-Text PDF

One Autopsy Proved Neocortical Lewy Body Disease Without the Involvement of the Olfactory Bulb and Brainstem.

J Korean Med Sci 2022 Jun 13;37(23):e195. Epub 2022 Jun 13.

Inje University Busan Paik Hospital Brain Bank, Busan, Korea.

Lewy bodies (LBs) and Lewy neurites (LNs) are pathological hallmarks of Parkinson's disease (PD) or dementia with LBs (DLB). Incidental Lewy body disease (iLBD) is defined when LBs and LNs are found in the brain of normal elderly individuals. A 65-year-old man presented with autopsy-proven Lewy body pathology (LBP). Read More

View Article and Full-Text PDF

Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia.

J Parkinsons Dis 2022 Jun 4. Epub 2022 Jun 4.

Eli Lilly and Company, Indianapolis, IN, USA.

Background: PRESENCE was a Phase 2 trial assessing mevidalen for symptomatic treatment of Lewy body dementia (LBD). Participants received daily doses (10, 30, or 75 mg) of mevidalen (LY3154207) or placebo for 12 weeks.

Objective: To evaluate if frequent cognitive and motor tests using an iPad app and wrist-worn actigraphy to track activity and sleep could detect mevidalen treatment effects in LBD. Read More

View Article and Full-Text PDF

Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?

Authors:
Kurt A Jellinger

Parkinsonism Relat Disord 2022 Jul 3;100:24-32. Epub 2022 Jun 3.

Institute of Clinical Neurobiology, Vienna, Austria, Alberichgasse 5/13, A-1150, Vienna, Austria. Electronic address:

Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) are two major neurocognitive disorders in the spectrum of Lewy body diseases that overlap in many clinical and neuropathological features, although they show several differences. Clinically distinguished mainly based on the duration of parkinsonism prior to development of dementia, their morphology is characterized by a variable combination of Lewy body (LB) and Alzheimer's disease (AD) pathologies, the latter usually being more frequent and severe in DLB.

Objective: The aims of the study were to investigate essential neuropathological differences between PDD and DLB in a larger cohort of autopsy cases. Read More

View Article and Full-Text PDF